Start Date: September 26th, 2017
Start Time: 4:00PM
End Time: 6:30PM
City: Washington, DC
Contact Address: 1400 Pennsylvania Ave. NW
Contact Name: Samantha Hunter
Email: [email protected]
The 2017 Roundtable Discussion, held on Tuesday, September 26, 2017, at the Willard InterContinental Hotel, focused on CMS and FDA Progress on Improving Health Outcomes for Older Patients.
The U.S. Food and Drug Administration (FDA) had a transformational year in 2016. The FDA produced negotiated agreements to reauthorize the prescription drug and medical device user fee programs and Congress passed the 21st Century Cures Act (Cures). The user fee agreements included enhancements and substantial workforce investments to further integrate patient perspectives and real-world evidence into the evaluation of new medical products. Cures also included funding and authorities intended to accelerate access to new medical products by modernizing the drug and device development processes.
The Centers for Medicare & Medicaid Services (CMS) made significant strides in 2016 to advance value and outcomes based payment. CMS reached peak provider interest in delivering care through value-based initiatives established under MACRA, the Medicare Access and CHIP Reauthorization Act. These initiatives were designed to improve quality and decrease cost in Medicare by sharing risk. MACRA put the Medicare program on track to have more than half of all payments tied to a value-based model by 2018. This shift has been slower to take place in the drug and device sectors due to impediments like anti-kickback statues, however, an increasing number of medical product manufactures are exploring outcomes-driven payment agreements to help drive quality, create savings and slow cost growth.
This expert roundtable, convened by the Alliance for Aging Research, provided leaders from the FDA and CMS with the opportunity to reflect on progress their agencies have made in implementing major policy changes to improve the health of older adults and offered their insights on future changes that may positively impact healthcare innovation.
Susan Peschin, MHS
President and CEO
Alliance for Aging Research
Dr. Janet Woodcock, MD
Director, Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Jean Moody-Williams, RN, MPP
Deputy Director, Center for Clinical Standards and Quality
Centers for Medicare and Medicaid Services
Senior Director, Government Strategy, Federal Accounts and Quality
Eli Lilly & Company
Head of Government Affairs and Policy
Susan C. Winckler
President, LP Consulting
Leavitt Partners, LLC
Deputy Health Policy Director & Senior FDA Policy Advisor
Senate HELP Committee Republican Staff
United States Senate
Thank You to Our Sponsors
2017 Annual Bipartisan Congressional Awards Dinner